Pre-made Mitumomab benchmark antibody (Whole mAb, anti-ganglioside GD3 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-ganglioside GD3 therapeutic antibody (Pre-made Mitumomab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Mitumomab (BEC-2) is a mouse anti-BEC-2 monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. It was developed by ImClone and Merck.[1]
| Products Name (INN Index) | Pre-Made Mitumomab Biosimilar, Whole Mab: Anti-Ganglioside Gd3 therapeutic antibody |
|---|---|
| INN Name | mitumomab |
| Target | ganglioside GD3 |
| Format | Whole mAb |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | IgG2b – kappa |
| VD LC | IgG2b – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Merck?KgaA (Darmstadt Germany) / ImClone Systems?Inc. (Somerville NJ USA) / Memorial Sloan-Kettering Cancer?Center (New York NY USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ganglioside GD3 |
| Package |
